FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
Keyword: BRCA1, Categories Cancer Treatment
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Study : Quality of life for people with early-stage breast cancer who participated in the OlympiA clinical trial
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with inherited mutations in BRCA1 or BRCA2 who have been diagnosed with early-stage, HER2-negative breast cancer.
The OlympiA study showed that the PARP inhibitor olaparib (Lynparza) is effective when used as maintenance therapy for people with an inherited BRCA1 or BRCA2 mutation who have early-stage breast cancer. Patient-reported outcomes from OlympiA suggest that olaparib was well tolerated and did not reduce quality of life or delay recovery from chemotherapy. (posted 2/22/22) Update: Based on OlympiA results, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who were diagnosed with early-stage HER2-negative breast cancer at high risk for recurrence. (03/11/2022).
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation
The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Patient outcomes and experiences of going flat
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Women considering mastectomy without breast reconstruction.
Some patients with early-stage breast cancer or those considering risk-reducing surgery may choose mastectomy without reconstruction. This is often referred to as “going flat.” The results of this study suggest that surgeons play a significant role in supporting a patient’s decision to go flat. (3/23/2021)
Este artículo está disponible en español.
Read More
Update : FDA approves the PARP inhibitor olaparib (Lynparza) in combination with bevacizumab (Avastin) as maintenance therapy for some women with advanced ovarian cancer
Most relevant for: Women with advanced ovarian cancer whose tumor has a BRCA mutation or a type of tumor marker called homologous recombination deficiency (HRD)
The FDA has approved the first drug combination to be used as a first-line maintenance therapy for some women with advanced ovarian cancer. (7/7/2020)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Promising research using a PARP inhibitor to treat metastatic breast cancer in people with an inherited PALB2 mutation or a tumor mutation in BRCA1 or BRCA2
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with metastatic breast cancer with an inherited mutation in PALB2 or tumor with a BRCA mutation
Early results of a small study showed that women with metastatic breast cancer and an inherited mutation in PALB2 or an acquired tumor mutation in BRCA1 or BRCA2 benefitted from the PARP inhibitor olaparib (Lynparza). (6/18/20)
Read More
Update : PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) receive FDA approval for metastatic prostate cancer
Most relevant for: Men with metastatic castration-resistant prostate cancer who have certain inherited or tumor mutations in DNA repair genes
The FDA approved two PARP inhibitors, rucaparib (Rubraca) and olaparib (Lynparza) for treatment of metastatic castration-resistant prostate cancer (mCRPC) in men who have certain inherited mutations or tumor mutations. (6/1/20)
Read More
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising
Relevance: Medium-High
Strength of Science: Medium-High
Research Timeline: Human Research
Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation
The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)
Read More
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Study : Inherited mutations in metastatic breast cancer patients
Relevance: Medium-High
Strength of Science: Medium
Research Timeline: Post Approval
Most relevant for: People with metastatic breast cancer
Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)
Read More
Relevance: High
Strength of Science: High
Research Timeline: Human Research
Study : Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.
Relevance: High
Strength of Science: High
Research Timeline: Human Research
Most relevant for: People diagnosed with pancreatic cancer who have a BRCA mutation
Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.
The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy. (7/3/19)
Read More
Relevance: Medium-High
Research Timeline: Post Approval
Guideline : Breast surgeons recommend genetic testing for all breast cancer patients
Relevance: Medium-High
Research Timeline: Post Approval
Most relevant for: Anyone diagnosed with breast cancer
The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)
Read More